These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pulmonary Hypertension Induced by Right Pulmonary Artery Occlusion: Hemodynamic Consequences of Todesco A; Grynblat J; Akoumia KKF; Bonnet D; Mendes-Ferreira P; Morisset S; Chemla D; Levy M; Méot M; Malekzadeh-Milani SG; Tielemans B; Decante B; Vastel-Amzallag C; Habert P; Ghigna MR; Humbert M; Montani D; Boulate D; Perros F J Am Heart Assoc; 2024 Jul; 13(14):e034621. PubMed ID: 38979789 [TBL] [Abstract][Full Text] [Related]
3. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. Tojais NF; Cao A; Lai YJ; Wang L; Chen PI; Alcazar MAA; de Jesus Perez VA; Hopper RK; Rhodes CJ; Bill MA; Sakai LY; Rabinovitch M Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1559-1569. PubMed ID: 28619995 [TBL] [Abstract][Full Text] [Related]
4. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075 [TBL] [Abstract][Full Text] [Related]
5. Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. Lambert M; Boet A; Rucker-Martin C; Mendes-Ferreira P; Capuano V; Hatem S; Adão R; Brás-Silva C; Hautefort A; Michel JB; Dorfmuller P; Fadel E; Kotsimbos T; Price L; Jourdon P; Montani D; Humbert M; Perros F; Antigny F Cardiovasc Res; 2018 May; 114(6):880-893. PubMed ID: 29360952 [TBL] [Abstract][Full Text] [Related]
12. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation. Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556 [TBL] [Abstract][Full Text] [Related]
13. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Orriols M; Gomez-Puerto MC; Ten Dijke P Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104 [TBL] [Abstract][Full Text] [Related]
14. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Hong KH; Lee YJ; Lee E; Park SO; Han C; Beppu H; Li E; Raizada MK; Bloch KD; Oh SP Circulation; 2008 Aug; 118(7):722-30. PubMed ID: 18663089 [TBL] [Abstract][Full Text] [Related]
15. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension. Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577 [TBL] [Abstract][Full Text] [Related]
16. CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension. Kabwe JC; Sawada H; Mitani Y; Oshita H; Tsuboya N; Zhang E; Maruyama J; Miyasaka Y; Ko H; Oya K; Ito H; Yodoya N; Otsuki S; Ohashi H; Okamoto R; Dohi K; Nishimura Y; Mashimo T; Hirayama M; Maruyama K Respir Res; 2022 Apr; 23(1):87. PubMed ID: 35395852 [TBL] [Abstract][Full Text] [Related]
17. Phenotypic Characterization of Hadinnapola C; Bleda M; Haimel M; Screaton N; Swift A; Dorfmüller P; Preston SD; Southwood M; Hernandez-Sanchez J; Martin J; Treacy C; Yates K; Bogaard H; Church C; Coghlan G; Condliffe R; Corris PA; Gibbs S; Girerd B; Holden S; Humbert M; Kiely DG; Lawrie A; Machado R; MacKenzie Ross R; Moledina S; Montani D; Newnham M; Peacock A; Pepke-Zaba J; Rayner-Matthews P; Shamardina O; Soubrier F; Southgate L; Suntharalingam J; Toshner M; Trembath R; Vonk Noordegraaf A; Wilkins MR; Wort SJ; Wharton J; ; Gräf S; Morrell NW Circulation; 2017 Nov; 136(21):2022-2033. PubMed ID: 28972005 [TBL] [Abstract][Full Text] [Related]
18. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Yasuda T; Tada Y; Tanabe N; Tatsumi K; West J Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L667-74. PubMed ID: 21856816 [TBL] [Abstract][Full Text] [Related]